Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
- DOI
- 10.1182/blood.2022018730
- Published
- 2023 Apr 6
- Container
- Blood
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/blood.2022018730,
title = {Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.},
author = {Abramson JS and Solomon SR and Arnason J and Johnston PB and Glass B and Bachanova V and Ibrahimi S and Mielke S and Mutsaers P and Hernandez-Ilizaliturri F and Izutsu K and Morschhauser F and Lunning M and Crotta A and Montheard S and Previtali A and Ogasawara K and Kamdar M},
year = {2023},
journal = {Blood},
doi = {10.1182/blood.2022018730},
url = {https://doi.org/10.1182/blood.2022018730}
}RIS
TY - JOUR TI - Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. AU - Abramson JS AU - Solomon SR AU - Arnason J AU - Johnston PB AU - Glass B AU - Bachanova V AU - Ibrahimi S AU - Mielke S AU - Mutsaers P AU - Hernandez-Ilizaliturri F AU - Izutsu K AU - Morschhauser F AU - Lunning M AU - Crotta A AU - Montheard S AU - Previtali A AU - Ogasawara K AU - Kamdar M PY - 2023 JO - Blood DO - 10.1182/blood.2022018730 UR - https://doi.org/10.1182/blood.2022018730 ER -
APA
JS, A., SR, S., J, A., PB, J., B, G., V, B., S, I., S, M., P, M., F, H., K, I., F, M., M, L., A, C., S, M., A, P., K, O., & M, K. (2023). Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.. Blood. https://doi.org/10.1182/blood.2022018730
Source records
- pubmed · retrieved 2026-09-25T18:27:15.645Z